سعر انيرزاير 150/50/160مكجم 30 كبسولة 2024

Indacaterol 150 mcg / glycopyrronium 50 mcg / mometasone furoate 160 mcg per capsule, inhalation powder hard capsules, 30 capsules + Breezhaler inhaler (Novartis Enerzair).

• Maintenance treatment of asthma in adults not adequately controlled with a maintenance combination of a LABA and a high-dose inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.Population: AdultsEuropean Medicines Agency (EMA)
• Directory (Arabic): bronchodilator improving respiratory function and treating asthma attacks.

• Most common over 52 weeks: asthma exacerbation (41.8%), nasopharyngitis (10.9%), upper respiratory tract infection (5.6%) and headache (4.2%).International label, same product · European Medicines Agency (EMA)

• Hypersensitivity to the active substances or to any of the excipients.International label, same product · European Medicines Agency (EMA)

• Not for acute asthma symptoms or bronchospasm (use a short-acting bronchodilator); do not stop abruptly. Also: paradoxical bronchospasm, cardiovascular effects, hypokalaemia and hyperglycaemia with beta-agonists, anticholinergic effects (e.g., narrow-angle glaucoma, urinary retention), caution in severe renal impairment, oropharyngeal infections (rinse mouth), systemic corticosteroid effects.International label, same product · European Medicines Agency (EMA)

• Beta-adrenergic blockersMay weaken or antagonise the effect of beta2-agonists (SmPC interaction heading).European Medicines Agency (EMA)
• Strong CYP3A4 and P-glycoprotein inhibitorsInteraction with CYP3A4/P-gp inhibitors listed in the SmPC (may increase systemic exposure).European Medicines Agency (EMA)

• Insufficient human data; mometasone furoate caused fetal malformations in animals; beta2-agonists may inhibit labour. Use in pregnancy only if expected benefit justifies the potential risk to the foetus.International label, same product · European Medicines Agency (EMA)
• No information on excretion in human milk (components detected in rat milk); decide whether to discontinue breastfeeding or therapy.International label, same product · European Medicines Agency (EMA)

• Indacaterol (as acetate): Long-acting beta2-agonist bronchodilator (SmPC class).
• Glycopyrronium (as bromide): Anticholinergic (muscarinic antagonist) bronchodilator (SmPC class).
• Mometasone furoate: Inhaled corticosteroid with anti-inflammatory action (SmPC class).